LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
its support of the Society for Minimally Invasive Spine Surgery (SMISS)
as it initiates the first prospective patient data registry related
specifically to minimally invasive spine surgery.
On Saturday, October 22nd, during the SMISS Annual Meeting in Las Vegas,
NV, the Prospective Data Registry was officially launched, with Orthofix
being recognized as one of the key founding sponsors for this program.
Bryan McMillan, President Global Spine Business Unit, stated, "We are
proud to support SMISS in this important initiative. We believe the
SMISS data registry will demonstrate the benefits of minimally invasive
spine surgery for the patient, surgeon, and hospital."
Choll Kim, M.D., PhD, Executive Director of SMISS, commented, "SMISS is
pleased to partner with Orthofix, who has innovative MIS products and
the vision to be a founding sponsor of our effort to collect key
clinical information on outcomes, complications, adverse events, as well
as the cost of treatment for minimally invasive spine surgery."
The multi-center program will enroll up to 250 subjects and outcomes
analysis will include a minimum two-year follow up. The primary
objectives of the registry will be to determine the rate and incidence
of peri-operative and post-operative adverse events in the MIS approach
for the treatment of spondylolisthesis, degenerative disc disease,
spinal stenosis, disc herniation, and degenerative scoliosis. In
addition, Health Related Quality of Life (HRQOL) and Quality Adjusted
Life Years (QALY) will be determined.
About Orthofix
Orthofix International N.V. is a global medical device company offering
a broad line of minimally invasive surgical, and non-surgical products
for the spine, orthopedics, and sports medicine market sectors that
address the lifelong bone-and-joint health needs of patients of all ages
helping them achieve a more active and mobile lifestyle. Orthofix's
products are widely distributed around the world to orthopedic surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
including BREG, Inc., and via collaborations with other leading
orthopedic product companies. In addition, Orthofix is collaborating on
R&D activities with leading research and clinical organizations such as
the Musculoskeletal Transplant Foundation, the Orthopedic Research and
Education Foundation, Texas Scottish Rite Hospital for Children, and the
Cleveland Clinical Foundation. For more information about Orthofix,
please visit www.orthofix.com.
Orthofix International N.V.
Mark Quick, 214-937-2924
Director
of Investor Relations and Business Development
markquick@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media